4
Changes in Ownership
Oruka Therapeutics, Inc. Filed Acc 0000907654-26-000037
Chief Operating Officer sold 5,000 shares at an average $63.88 ($319,384)
- Chief Operating Officer acquired 5,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Sandler Laura Lee · Chief Operating Officer
Table I: Non-derivative
7 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-05-01 | Exercise or conversion : show line 1 in the form 10b5-1 | +5,000 | $7.80 | $39,000 | 241,984 | D |
| 2026-05-01 | Sale : show line 2 in the form 10b5-1 | −2,200 | $62.58 | $137,685 | 239,784 | D |
| 2026-05-01 | Sale : show line 3 in the form 10b5-1 | −1,800 | $64.15 | $115,468 | 237,984 | D |
| 2026-05-01 | Sale : show line 4 in the form 10b5-1 | −300 | $65.10 | $19,530 | 237,684 | D |
| 2026-05-01 | Sale : show line 5 in the form 10b5-1 | −400 | $66.06 | $26,422 | 237,284 | D |
| 2026-05-01 | Sale : show line 6 in the form 10b5-1 | −200 | $67.16 | $13,431 | 237,084 | D |
| 2026-05-01 | Sale : show line 7 in the form 10b5-1 | −100 | $68.48 | $6,848 | 236,984 | D |
| Open-market sales · 5,000 sh · avg $63.88 · $319,384 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-05-01 | Exercise or conversion : show line 8 in the form 10b5-1 Employee Warrant (right to buy) | −5,000 | 84,996 | D |
Loading xslF345X06/form4.xml…